Clinical Trials Logo

Dysgerminoma clinical trials

View clinical trials related to Dysgerminoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03158064 Active, not recruiting - Germ Cell Tumor Clinical Trials

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Start date: May 15, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of durvalumab with tremelimumab in patients with relapsed or refractory germ cell tumors.

NCT ID: NCT01080521 Completed - Clinical trials for Ovarian Endometrioid Adenocarcinoma

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Start date: April 2010
Phase:
Study type: Observational

This clinical trial is studying changes in brain function in patients with stage I, stage II, stage III, or stage IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy. Learning about the effects of chemotherapy on brain function may help doctors plan cancer treatments.

NCT ID: NCT00204633 Completed - Dysgerminoma Clinical Trials

Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)

Start date: July 2003
Phase: Phase 2
Study type: Interventional

The aim is to determine the frequency of RBC transfusion in patients with metastatic "poor prognosis" germ cell tumor during high-dose chemotherapy (HD-VIP, level 6) with or without Darbepoetin alfa

NCT ID: NCT00042952 Terminated - Clinical trials for Recurrent Ovarian Germ Cell Tumor

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

Start date: June 2002
Phase: Phase 2
Study type: Interventional

Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have progressive, refractory, or recurrent stage II or stage III testicular cancer or stage II or stage III ovarian cancer following cisplatin-based chemotherapy